We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $2.05B
1-Year Est. Return 161.37%
This Fund
S&P 500
This Quarter Est. Return
+4.87%
1 Year Est. Return
+161.37%
3 Year Est. Return
+342.48%
5 Year Est. Return
+531.16%
10 Year Est. Return
+6,258.71%
AUM
$1.7B
AUM Growth
-$254M
Cap. Flow
-$154M
Cap. Flow %
-9.05%
Top 10 Hldgs %
40.6%
Holding
107
New
9
Increased
39
Reduced
24
Closed
7

Top Buys

Rank Stock Value
1
MMED
MiniMed Group Inc
MMED
+$17.4M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$15M
3
BSX icon
Boston Scientific
BSX
+$9.3M
4
HTFL
Heartflow Inc
HTFL
+$8M
5
PTCT icon
PTC Therapeutics
PTCT
+$7.08M

Top Sells

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$61.1M
2
CDTX
Cidara Therapeutics
CDTX
+$45.3M
3
FOLD
Amicus Therapeutics
FOLD
+$27.4M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$24M
5
TVTX icon
Travere Therapeutics
TVTX
+$21.9M

Sector Composition

Rank Sector Weight
1 Healthcare 99.77%
2 Miscellaneous 0.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLNO
51
DELISTED
Soleno Therapeutics
SLNO
$8.61M 0.51%
257,253
+10,200
+4% +$400K
MBX
52
MBX Biosciences
MBX
$3.03B
$8.6M 0.51%
287,967
+5,343
+2% +$182K
TNGX icon
53
Tango Therapeutics
TNGX
$3.94B
$8.09M 0.48%
386,915
– –
REGN icon
54
Regeneron Pharmaceuticals
REGN
$81.8B
$7.8M 0.46%
10,100
– –
IMNM icon
55
Immunome
IMNM
$3.13B
$7.6M 0.45%
347,666
– –
AMLX icon
56
Amylyx Pharmaceuticals
AMLX
$3.87B
$6.95M 0.41%
499,764
– –
OMDA
57
Omada Health Inc
OMDA
$1.45B
$6.8M 0.4%
541,000
-199,000
-27% -$2.75M
INSP icon
58
Inspire Medical Systems
INSP
$1.78B
$6.8M 0.4%
131,800
+800
+0.6% +$56K
APLS
59
DELISTED
Apellis Pharmaceuticals
APLS
$6.55M 0.39%
162,750
+12,250
+8% +$264K
ALKS icon
60
Alkermes
ALKS
$7.95B
$6.51M 0.38%
183,986
+44,758
+32% +$1.39M
EVH icon
61
Evolent Health
EVH
$520M
$6.1M 0.36%
2,675,000
– –
INDV icon
62
Indivior Pharmaceuticals
INDV
$4.12B
$6.1M 0.36%
200,000
+94,900
+90% +$3.13M
TERN
63
DELISTED
Terns Pharmaceuticals
TERN
$6M 0.35%
113,748
+5,267
+5% +$216K
FOCL
64
EDAP TMS S.A.
FOCL
$199M
$5.13M 0.3%
1,378,000
+91,500
+7% +$377K
JANX icon
65
Janux Therapeutics
JANX
$1.1B
$5.1M 0.3%
367,009
+8,211
+2% +$113K
PHR icon
66
Phreesia
PHR
$751M
$5.03M 0.3%
600,400
-276,200
-32% -$3.65M
TMO icon
67
Thermo Fisher Scientific
TMO
$230B
$4.92M 0.29%
10,000
– –
SYK icon
68
Stryker
SYK
$127B
$4.86M 0.29%
+14,800
New +$5.31M
SION
69
Sionna Therapeutics
SION
$265M
$3.99M 0.23%
99,429
– –
RCUS icon
70
Arcus Biosciences
RCUS
$3.72B
$3.89M 0.23%
180,000
– –
XBI icon
71
State Street SPDR S&P Biotech ETF
XBI
$11.3B
$3.83M 0.23%
30,000
-192,000
-86% -$24M
ATEC icon
72
Alphatec Holdings
ATEC
$1.46B
$3.81M 0.22%
350,000
+47,500
+16% +$691K
PCVX icon
73
Vaxcyte
PCVX
$8.9B
$3.5M 0.21%
60,250
+13,250
+28% +$719K
EYPT icon
74
EyePoint Inc
EYPT
$386M
$3.34M 0.2%
258,739
– –
NVO
75
Novo Nordisk
NVO
$202B
$3.31M 0.19%
+90,000
New +$4.26M
1 2
3
4 5

Similar funds

ABI
Abrams Bison Investments Bethesda, Maryland $2.05B AUM 71.03% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
JCM
Jacobi Capital Management Pittston, Pennsylvania $2.04B AUM 26.26% 1-Year Est. Return

Rock Springs Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Rock Springs Capital Management held 107 positions worth $1.7B, down 13% from $1.95B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Rock Springs Capital Management withdrew a net $154M in Q1 2026, closing 7 positions and reducing 24 holdings. Its most notable exit was Exact Sciences, an estimated $61.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Miscellaneous.

Against the trend, Rock Springs Capital Management opened a new position in MiniMed Group Inc worth $15.7M.

  • Rock Springs Capital Management's largest Q1 2026 buy was MiniMed Group Inc: 1,055,000 shares worth $15.7M.
  • Rock Springs Capital Management added most to Madrigal Pharmaceuticals in Q1 2026, an estimated $15M increase.
  • Rock Springs Capital Management's biggest Q1 2026 reduction was Amicus Therapeutics, cutting an estimated $27.4M.
  • Rock Springs Capital Management fully exited Exact Sciences in Q1 2026, selling an estimated $61.1M.
  • Rock Springs Capital Management's ten largest holdings make up 41% of its $1.7B portfolio in Q1 2026.
  • Rock Springs Capital Management opened 9 new positions and closed 7 in Q1 2026.
  • Rock Springs Capital Management's portfolio value fell 13% quarter-over-quarter to $1.7B.

Based on Rock Springs Capital Management's 13F filing for Q1 2026, filed 15 May 2026.